CN1332675C - Medicine application of catalpa and extractive for anti allergic disease - Google Patents
Medicine application of catalpa and extractive for anti allergic disease Download PDFInfo
- Publication number
- CN1332675C CN1332675C CNB200410103549XA CN200410103549A CN1332675C CN 1332675 C CN1332675 C CN 1332675C CN B200410103549X A CNB200410103549X A CN B200410103549XA CN 200410103549 A CN200410103549 A CN 200410103549A CN 1332675 C CN1332675 C CN 1332675C
- Authority
- CN
- China
- Prior art keywords
- catalpa
- extract
- total glycosides
- catalpae ovatae
- extractive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to an application of plant extracts of bignoniaceae Catalpa L. for preparing medicines for treating and preventing asthma diseases, chronic obstructive pulmonary diseases and anaphylaxies. The extracts of Catalpa plant iridoid total glycosides have obvious antiinflammatory, antianaphylaxis and antasthmatic activities, are a natural medicine for treating and preventing anaphylactic diseases which comprise chronic obstructive pulmonary diseases, allergic asthma diseases and allergic rhinitis, and have no venenous and side effect of the existing familiar medicines for treating chronic obstructive pulmonary diseases, allergic asthmas and other anaphylactic diseases.
Description
Technical field
The present invention relates to field of medicaments, a kind of medical usage that effectively prevents and treat the natural plant extracts of asthma, chronic obstructive pulmonary disease (COPD), irritated disease.The present invention is specially adapted to treatment and prevention of asthma.Also can be used for treatment and Polyglucan rhinitis and anaphylaxis dermatosis.
Background technology
Asthma is the respiratory tract anaphylaxis reactive inflammation disease that allergen causes.Allergen is the key factor that causes pathogenesis of asthma and development, and allergen is deposited on the air flue mucosa after sucking air flue, causes airway allergy inflammation by local and systemic immune response.Sucking allergen causes airway allergy inflammation branch sensitization and causes scorching two stages.Atopy patient produces sensitization after beginning to suck certain allergen, and body can be sensitiveness to this allergen.In the sensitization stage, it is that air flue produces and the corresponding specificity antibody IgE of allergen that body mainly changes, mastocyte in this antibody IgE and the air flue, acidophil and hugely have a liking for cell affinity is all arranged, these interior cells of these specificity antibody IgEs and air flue combine the sensitization state that has formed air flue and body.Can cause activation and release inflammatory mediators such as mastocyte when identical allergen sucks air flue once more, cause air flue allergenicity inflammation and cause asthma attack, Here it is causes the scorching stage.It also is the pathogenic process of asthma.
Bronchial asthma is chronic respiratory tract disease the most common in the world wide, and the conservative estimation whole world has at least the people more than 100,000,000 to suffer from asthma, in recent years, and because of its prevalence and mortality rate all are taking advantage of a favourable situation of rising.Asthma has become serious public health problem and has received the very big concern of countries in the world.Therefore need provide the medicine and the method for the treatment of asthma effectively.
In the last thirty years, a large amount of development and researches has been carried out to the medicine of treatment asthma in the whole world.The medicine of the treatment asthma that has developed has β
2-3 adrenergic receptor agonists class, alpha-adrenergic aceptor antagonist class, aminophylline class, cholinoceptor antagonist class, calcium ion antagonist class, potassium-channel agonist, glucocorticoid, cell membrane stability agent (sodium cromoglicate, Buddhist nun examine a meter sodium more), antihistamine drug, LTRA, platelet activating factor (PAF) antagonist, specific active immunotherapy agent, nonspecific immunity therapeutic agent etc.Asthma is the very complicated multi-factor disease of a kind of mechanism, is the diseases associated with inflammation that the many cells multimedium participates in.Above-mentioned these medicines (perhaps Therapeutic Method) mechanism of action single (to a kind of or two, three kind of medium, the factor, receptor or passage work), these medicines or therapeutic effect not obvious or oral invalid must the special pathway administration or side effect greatly can't life-time service.What generally adopt clinically at present also is that the most effective Therapeutic Method is to suck glucocorticoid (light moderate sucks sodium cromoglicate, the Buddhist nun examines a meter sodium more) anti-inflammatory treatment for a long time, sucks β during asthma attack
2Bronchodilators such as-3 adrenergic receptor agonists, cholinoceptor antagonist.These Therapeutic Method are to relieving asthma symptoms, and there is certain effect the quality of life of improving asthma patient, but the M ﹠ M of asthma is decreased.Reduce the M ﹠ M of asthma, the prognosis that improves asthma still lack effective means (Li Minghua etc., asthma, the People's Health Publisher, 1998, p2).The treatment asthma needs more effective and safer medicine.
The cause of disease of chronic obstructive pulmonary disease is at present also not clear, but relevant with airway inflammation be sure, use long-term glucocorticoid anti-inflammatory treatment and the suction β of sucking at present
2The treatment of bronchodilators such as-3 adrenergic receptor agonists, cholinoceptor antagonist is that certain effect is arranged.But the therapeutic effect of these medicines is not very good, and the medicine of seeking more effective treatment chronic obstructive pulmonary disease is very important.
Summary of the invention
The present invention relates to treat the Chinese medicine pharmaceutical composition of asthma and other anaphylactic disease, particularly with catalpa and the iridoids that contained thereof natural medicinal formulations for its effective ingredient.
The Bignoniaceae Chinese catalpa belongs to (Catalpa L.) plant and comprises Catalpa ovata Don. (C.ovata G.Don), Chinese catalpa (C.bungeiC.A.wey.), Catalpa bungei (C.fargesii Bar.) and Catalpa (C.speciosa Ward.), and they all contain catalposide, catalpol or are other iridoid glycoside compounds of basic structure with the catalpol.
The existing Catalpa ovata Don. (C.ovata G.Don) of existing medical information, Chinese catalpa (C.bungeiC.A.wey.), the record of Catalpa bungei catalpa medical usages such as (C.fargesii Bar.), mainly contain effects such as heat clearing away, pain relieving, diuresis, detumescence, be mainly used in treatment rheumatism hectic fever, limbs pain, arthritis, chronic nephritis, edema etc., all do not treat the saying of anaphylactic disease, do not treat the record of asthma and rhinitis yet.
Be used to prepare the treatment asthma, treat the catalpa of the catalpa total glycosides extractive of chronic obstructive pulmonary disease, anaphylactic disease, being the Herb of Catalpa ovata Don. or Chinese catalpa or Catalpa bungei or Catalpa, is their leaf and/or flower and/or fruit and or bark and or root bark.
The purpose of this invention is to provide the application in the pharmaceutical preparation of preparation treatment asthma, treatment chronic obstructive pulmonary disease, anaphylactic disease and diseases associated with inflammation of catalpa and catalpa extract thereof.The catalpa extract extracts from catalpa, comprises water extract, alcohol extract, the water-alcohol extraction of catalpa, and the material that extracts from catalpa with other solvent.Especially, be meant the total glycosides extractive that the iridoids chemical constituent is an effective ingredient that contains that extracts from catalpa, the catalpa total glycosides extractive mainly is made up of following chemical constituent: catalposide, catalpol (catalpol) or be other iridoid glycoside compounds of basic structure with the catalpol.Especially, described catalpa total glycosides extractive iridoid glycoside content is not less than 50%.
Characteristics such as the catalpa extract is a kind of have treatment asthma, treatment chronic obstructive pulmonary disease, active plant extract of antiallergic pharmacology, and it is little to have toxicity, and the life-time service curative effect is preferable.
The Wistar healthy mice is used in the acute toxicity test of catalpa extract, and oral maximum dosage-feeding is equivalent to not see animal dead more than the catalpa crude drug 120g/kg; Intraperitoneal injection LD
50Be equivalent to crude drug 40/kg, intravenous administration LD
50Be 15～30g/kg.
Iridoid glycoside content is done acute toxicity test greater than 50% catalpa total glycosides extractive with the Wistar healthy mice, and oral maximum dosage-feeding is 40.7g/kg, does not see animal dead; Intraperitoneal injection LD
50Be 15.0～25.0g/kg, intravenous administration LD
50Be 2.00～3.00g/kg.
Catalpa total glycosides extractive provided by the invention can mix with one or more pharmaceutically acceptable stone compositions, and contains in the compositions of catalpa total glycosides extractive and further contain β
2-3 adrenergic receptor agonists.
The invention provides the method that the treatment mammal breathes the immune-mediated inflammatory diseases in road, described method comprises the catalpa iridoid total glucoside extract to described administration treatment effective dose, or use the pharmaceutical composition that contains catalpa iridoid total glucoside extract, or further contain β
2The described compositions of-3 adrenergic receptor agonists.
The pharmaceutical composition of catalpa total glycosides extractive can be a various forms, comprises peroral dosage form, the solution of suction form and injectable and infusion.When using with inhalant or aerosol form, the catalpa total glycosides extractive is used in combination with the dry powder that pharmaceutically acceptable carrier solution maybe can change into the form of aerosol.Similarly, when using with oral administration, the catalpa total glycosides extractive is used in combination with the pharmaceutically acceptable carrier that is used in oral administration.When being used for the treatment of immune-mediated inflammatory dermatosis, the catalpa total glycosides extractive can be used in combination with nontoxic, pharmaceutically acceptable topical vehicle.The catalpa total glycosides extractive can with the treating asthma agent, as β
2-3 adrenergic receptor agonists, cholinoceptor antagonist, aminophylline class, glucocorticoid, antihistamine drug etc. are used in combination.
The catalpa total glycosides extractive is used to prevent and treat immune-mediated inflammatory diseases, particularly comprises the disease relevant with respiratory tract of asthma, and particularly relevant with chronic asthma immunne response is crossed strong and allergic rhinitis.Therefore the present invention also provides the method for the treatment of immune-mediated disease, and this method comprises to the catalpa ring total glycosides extractive that has immune-mediated inflammatory diseases patient with treatment effective dosage forms and dosage.
The catalpa total glycosides extractive is used for prevention and treatment chronic obstructive pulmonary disease.
The dosage of catalpa extract of the present invention, because of patient's state, body weight, administering mode etc. different different.Such as under non-oral situation, intramuscular, vein, enteral administration, calculate 0.20mg-2000mg/kg. day with the catalpa crude drug, preferred one 200mg/kg. day of 2.0mg, calculate 2.0-20g/kg. day with the catalpa crude drug under the oral situation, preferred 20-2000mg/kg. day.
Iridoid glycoside content of the present invention is greater than the dosage of 50% catalpa total glycosides extractive, because of patient's state, body weight, administering mode etc. different different.Such as under non-oral situation, intramuscular, vein, enteral administration 0.01mg-100mg/kg. day, preferred 0.1mg-10mg/kg. day, 0.1-1000mg/kg. day under the oral situation, preferred 1-100mg/kg. day.
The specific embodiment
With following embodiment the present invention is specified, but the present invention is not limited to the content that the following example comprises.
[embodiment one] gets Fructus catalpae ovatae 2kg, water 16000ml boils and extracted 1 hour, the leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, and leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, the leaching extracting solution, merge aqueous extract, vacuum concentration gets the Fructus catalpae ovatae extract to doing.
Get Catalpa ovata Don. leaf 2kg, water 16000ml boils and extracted 1 hour, and leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, leaching extracting solution, merge aqueous extract, vacuum concentration gets the Folium catalpae ovatae extract to doing.
Get Fructus catalpae ovatae 2kg, water 16000ml boils and extracted 1 hour, the leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, the leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, and the leaching extracting solution merges aqueous extract, remove precipitation (if any precipitation), by the active carbon detached dowel, the conventional flush away impurity of water is to closely colourless, and sugared reaction test feminine gender (molish reaction negative), it is closely colourless that continuous Diluted Alcohol with 7% is washed till eluent, and after the sugared reaction test feminine gender (molish reaction negative), the ethanol 4000ml eluting with 40%.40% ethanol elution vacuum concentration under agitation adds ethanol 1000ml to 500ml, leaves standstill, and divides and to get upper strata liquid, is evaporated to driedly, promptly get Fructus catalpae ovatae total glycosides extractive 115 and restrains, and iridoid glycoside content is 51.4%.
Get Catalpa ovata Don. leaf 2kg, water 16000ml boils and extracted 1 hour, the leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, the leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, and the leaching extracting solution merges aqueous extract, remove precipitation (if any precipitation), by the active carbon detached dowel, the conventional flush away impurity of water is to closely colourless, and sugared reaction test feminine gender (molish reaction negative), it is closely colourless that continuous Diluted Alcohol with 7% is washed till eluent, and after the sugared reaction test feminine gender (molish reaction negative), the ethanol 4000ml eluting with 40%.40% ethanol elution vacuum concentration under agitation adds ethanol 1500ml to 500ml, leaves standstill, and divides and to get upper strata liquid, is evaporated to driedly, promptly get Folium catalpae ovatae total glycosides extractive 80.3 and restrains, and iridoid glycoside content is 53.4%.
The ovalbumin aerosol sucks to draw breathes heavily test
Get 60 of 200-250g Cavia porcelluss, male and female half and half, prior to right rear leg outside intramuscular injection 4% ovalbumin normal saline solution 0.2ml/ only, while lumbar injection 4% gel aluminum hydroxide 0.2ml sensitization.From sensitization second day, animal was divided into 5 groups at random: matched group, Fructus catalpae ovatae extract group, Folium catalpae ovatae extract group, Fructus catalpae ovatae total glycosides extractive group, Folium catalpae ovatae total glycosides extractive group.The administration group is pressed table one administration, totally 14 days, behind the last medicine, animal is put in the airtight glass bell jar, after treating peace and quiet, start air compressor, spray into 30 seconds of 3.5% ovalbumin normal saline, observe incubation period and the number of animals that tic takes place that the tic of panting property appears in Cavia porcellus in 6 minutes with the constant voltage of 53kPa (400mmHg).(Xu Shuyun, Bian Rulian, Chen Xiu chief editor, pharmacological experimental methodology, the People's Health Publisher, in November, 1991 second edition, 1199 pages).
Table one, Fructus catalpae ovatae and Folium catalpae ovatae extract draw the influence that Cavia porcellus breathes heavily to medicine
| Group | Number of animals (n) | Dosage (g/kg) | Draw and breathe heavily incubation period (second) |
| Contrast | 10 | - | 62.9±27.6 |
| The Fructus catalpae ovatae extract | 10 | 4.0 | 151.6±89.8** |
| The Folium catalpae ovatae extract | 10 | 4.0 | 156.4±89.2** |
| The Fructus catalpae ovatae total glycosides extractive | 10 | 0.15 | 142.5±96.4* |
| The Folium catalpae ovatae total glycosides extractive | 10 | 0.15 | 147.5±95.3* |
Annotate: * and show and blank group comparison P＜0.05 significant difference that * * shows and blank group comparison P＜0.01 difference highly significant.
Result of the test shows, Fructus catalpae ovatae extract, Folium catalpae ovatae extract, Fructus catalpae ovatae total glycosides extractive, Folium catalpae ovatae total glycosides extractive all can draw the incubation period of breathing heavily Cavia porcellus by significant prolongation ovalbumin normal saline solution, compare with matched group that there were significant differences (P＜0.05), show that Fructus catalpae ovatae extract, Folium catalpae ovatae extract, Fructus catalpae ovatae total glycosides, Folium catalpae ovatae total glycosides all have certain antiasthmatic effect.
Passive cutaneous anaphylaxis test (PCA)
The rat body is divided into 5 groups at random by heavy, 10/group, ♀ ♂ half and half, sub-cage rearing, 5/cage.Be respectively 1 blank group, 4 reagent groups by table two administration.Test group adopts therapeutic administration Fructus catalpae ovatae extract, Folium catalpae ovatae extract, Fructus catalpae ovatae total glycosides extractive, Folium catalpae ovatae total glycosides extractive, successive administration 14d before antigen is attacked.
Antiserum Preparation: with four sole injections of above-mentioned Radix Trichosanthis aluminium hydroxide suspension, every sole injection 0.1ml, 0.4ml altogether.The 10-15d maturation, the about 10ml of eyeball blood-letting with the centrifugal 15min of 3000 commentaries on classics/min, gets upper serum and promptly gets antiserum.
Passive sensitization of skin: will test and respectively organize the rat back depilation, 2 points are respectively got apart from center line 1.5cm in the spinal column both sides, every some interval 2cm, the about 1 * 1cm2 of area, totally 4 points.In skin of back, inject sero-fast different dilution factors (1: 301: 40) respectively.Carrying out quantitative corresponding antigens behind the 48h attacks.The tail vein injection Radix Trichosanthis adds AZO-blue solution 1mg/kg, sacrificed by decapitation behind the 30min.
Observation index: the sero-fast local skin reaction of intradermal injection, and measure the locus coeruleus diameter that AZO-blue is oozed out.Calculate PCA and suppress percentage rate (%).PCA suppress percentage rate=(blank group locus coeruleus diameter-medication group locus coeruleus diameter)/blank group locus coeruleus diameter * 100% (Xu Shuyun, Bian Rulian, the Chen Xiu chief editor, pharmacological experimental methodology, the People's Health Publisher, in November, 1991 second edition, 1197 pages)
Table two, Fructus catalpae ovatae and Folium catalpae ovatae extract are to models of passive skin irritability of rats reaction influence
| Group | Number of animals (only) | Dosage g/kg | Different serum-concentration locus coeruleus diameters (cm) | |
| 1∶30 | 1∶40 | |||
| Contrast | 10 | Water | 1.55±0.23 | 0.91±0.22 |
| The Fructus catalpae ovatae extract | 10 | 4.0 | 0.98±0.23*** | 0.55±0.20* |
| The Folium catalpae ovatae extract | 10 | 4.0 | 0.96±0.21*** | 0.56±0.20* |
| The Fructus catalpae ovatae total glycosides extractive | 10 | 0.15 | 0.94±0.20*** | 0.60±0.21* |
| The Folium catalpae ovatae total glycosides extractive | 10 | 0.15 | 0.96±0.21*** | 0.62±0.22* |
Annotate: * * represents to compare P＜0.01 with the blank group, and * * * represents to compare P＜0.001 with the blank group
Result of the test sees Table two, from table the result as can be seen, reagent Fructus catalpae ovatae extract, Folium catalpae ovatae extract, Fructus catalpae ovatae total glycosides extractive, Folium catalpae ovatae total glycosides extractive were antiserum dilution factor 1: 30,1: 40 o'clock, show significance and suppress locus coeruleus diameter (P＜0.01), suppression ratio is 36.8% and 39.6%.Show that Fructus catalpae ovatae extract, Folium catalpae ovatae extract, Fructus catalpae ovatae total glycosides extractive, Folium catalpae ovatae total glycosides extractive all have certain inhibitory action to passive cutaneous anaphylaxis, PCA.
Tardy property footpad reaction test
Mice is pressed the body weight random packet, 10/group, ♀ ♂ half and half, sub-cage rearing, totally 5 groups, is respectively 1 blank group, 4 reagent groups by table three administration by 5/cage.Test group adopts therapeutic administration Fructus catalpae ovatae extract, Folium catalpae ovatae extract, Fructus catalpae ovatae total glycosides, Folium catalpae ovatae total glycosides, and administration 5d continues administration 5d before the sensitization to sensitization, altogether 10d.
0.05ml/ sensitization of NIH mice cervical region s.c5% sheep red blood cell (SRBC) (SRBC) behind the sensitization 5d.Right foot pad s.c5% sheep red blood cell (SRBC) 0.02ml attacks behind the 6d.Left side foot injection equivalent normal saline compares.Behind the 24h, last administration 50min puts to death animal.Cutting two foots from the ankle joint position weighs.Obtain the weight difference of two foots, calculate inhibitory rate of intumesce.Foot swelling suppression ratio=blank group foot swelling degree-medication group foot swelling degree)/and blank group foot swelling degree * 100%, result of the test sees Table 4.(chief editor such as Xu Shuyun, pharmacological experimental methodology, People's Health Publisher, second edition in 1991,1226 pages, 1228 pages)
The influence of the tardy property of the mice footpad reaction that table three, Fructus catalpae ovatae and Folium catalpae ovatae extract cause sheep red blood cell (SRBC)
| Group | Number of animals (only) | Dosage (g/kg) | Foot swelling degree (g) | Suppression ratio (%) |
| Contrast | 10 | Water | 2.51±0.73 | --- |
| The Fructus catalpae ovatae extract | 10 | 5.0 | 1.70±0.67* | 32.3 |
| The Folium catalpae ovatae extract | 10 | 5.0 | 1.68±0.63* | 33.1 |
| The Fructus catalpae ovatae total glycosides extractive | 10 | 0.6 | 1.72±0.68* | 31.5 |
| The Folium catalpae ovatae total glycosides extractive | 10 | 0.6 | 1.66±0.59* | 33.9 |
Annotate: * represents to compare P＜0.05 significant difference with the blank group.
From table three result as can be seen, Fructus catalpae ovatae extract, Folium catalpae ovatae extract, Fructus catalpae ovatae total glycosides extractive, Folium catalpae ovatae total glycosides extractive and blank group comparison sheet reveal significance and suppress foot swelling degree (P＜0.05), and suppression ratio is between 31%-34%.Show that Fructus catalpae ovatae extract, Folium catalpae ovatae extract, Fructus catalpae ovatae total glycosides extractive, Folium catalpae ovatae total glycosides extractive all have than the obvious suppression effect the tardy property of the mice immunoreation that sheep red blood cell (SRBC) causes.
[embodiment two] get the real 2kg of Chinese catalpa, water 16000ml boils and extracted 1 hour, the leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, and leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, the leaching extracting solution, merge aqueous extract, vacuum concentration gets the real extract of Chinese catalpa to doing.
Get Chinese catalpa leaf 2kg, water 16000ml boils and extracted 1 hour, and leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, leaching extracting solution, merge aqueous extract, vacuum concentration gets the Chinese catalpa leaf extract to doing.
Get the real 2kg of Chinese catalpa, water 16000ml boils and extracted 1 hour, the leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, the leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, and the leaching extracting solution merges aqueous extract, remove precipitation (if any precipitation), by active carbon (110 ℃ of activation of 1kg active carbon 4 hours) detached dowel, the conventional flush away impurity of water is to closely colourless, and sugared reaction test feminine gender (molish reaction negative), it is closely colourless that continuous Diluted Alcohol with 7% is washed till eluent, and after the sugared reaction test feminine gender (molish reaction negative), the ethanol 4000ml eluting with 40%.40% ethanol elution vacuum concentration under agitation adds acetone 500ml to 500ml, leaves standstill, and divides and to get upper strata liquid, is evaporated to driedly, promptly get the real total glycosides extractive 106.7 of Chinese catalpa and restrains, and iridoid glycoside content is 50.9%.
Get Chinese catalpa leaf 2kg, water 16000ml boils and extracted 1 hour, the leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, leaching extracting solution, merge aqueous extract, merge three times extracting solution, remove precipitation (if any precipitation), by active carbon (110 ℃ of activation of 1kg active carbon 4 hours) detached dowel, the conventional flush away impurity of water, to closely colourless, and sugared reaction test feminine gender (molish reaction negative), it is closely colourless that continuous Diluted Alcohol with 7% is washed till eluent, and after the sugared reaction test feminine gender (molish reaction negative), the ethanol 4000ml eluting with 40%.40% ethanol elution vacuum concentration under agitation adds acetone 500ml to 500ml, leaves standstill, and divides and to get upper strata liquid, is evaporated to driedly, promptly get Chinese catalpa leaves total glycoside extract 95.3 and restrains, and iridoid glycoside content is 53.6%.
The ovalbumin aerosol sucks to draw breathes heavily test
Get 60 of 200-250g Cavia porcelluss, male and female half and half, prior to right rear leg outside intramuscular injection 4% ovalbumin normal saline solution 0.2ml/ only, while lumbar injection 4% gel aluminum hydroxide 0.2ml sensitization.From sensitization second day, animal was divided into 5 groups at random: 1 matched group, 4 administration groups.The administration group is pressed table four gastric infusion, totally 14 days, behind the last medicine, animal is put in the airtight glass bell jar, after treating peace and quiet, start air compressor, spray into 30 seconds of 3.5% ovalbumin normal saline, observe incubation period and the number of animals that tic takes place that the tic of panting property appears in Cavia porcellus in 6 minutes with the constant voltage of 53kPa (400mmHg).(Xu Shuyun, Bian Rulian, Chen Xiu chief editor, pharmacological experimental methodology, the People's Health Publisher, in November, 1991 second edition, 1199 pages).
Table four, Chinese catalpa reality and Chinese catalpa leaf are carried the extract thing medicine are drawn the influence that Cavia porcellus breathes heavily
| Group | Number of animals (n) | Dosage (g/kg) | Draw and breathe heavily incubation period (second) |
| Contrast | 10 | - | 59.8±28.7 |
| The real extract of Chinese catalpa | 10 | 4.0 | 148.5±89.5* |
| The Chinese catalpa leaf extract | 10 | 4.0 | 152.6±95.0* |
| The real total glycosides extractive of Chinese catalpa | 10 | 0.15 | 142.5±86.4* |
| The Chinese catalpa leaves total glycoside extract | 10 | 0.15 | 148.4±90.5* |
Annotate: compare P＜0.01 difference highly significant, (representing) with * with the blank group.
Result of the test shows, the real extract of Chinese catalpa, Chinese catalpa leaf extract, the real total glycosides extractive of Chinese catalpa, Chinese catalpa leaves total glycoside extract all can draw the incubation period of breathing heavily Cavia porcellus by significant prolongation ovalbumin normal saline solution, compare with matched group that there were significant differences (P＜0.05), show that the real extract of Chinese catalpa, Chinese catalpa leaf extract, the real total glycosides extractive of Chinese catalpa, Chinese catalpa leaves total glycoside extract all have certain antiasthmatic effect.
Passive cutaneous anaphylaxis test (PCA)
The rat body is divided into 2 groups at random by heavy, 10/group, ♀ ♂ half and half, sub-cage rearing, 5/cage.Be respectively 1 blank group, 4 reagent groups by table two administration.Test group adopts the real extract of therapeutic administration Chinese catalpa, Chinese catalpa leaf extract, the real total glycosides extractive of Chinese catalpa, Chinese catalpa leaves total glycoside extract, successive administration 14d before antigen is attacked.
Antiserum Preparation: with four sole injections of above-mentioned Radix Trichosanthis aluminium hydroxide suspension, every sole injection 0.1ml, 0.4ml altogether.The 10-15d maturation, the about 10ml of eyeball blood-letting with the centrifugal 15min of 3000 commentaries on classics/min, gets upper serum and promptly gets antiserum.
Passive sensitization of skin: will test and respectively organize the rat back depilation, 2 points are respectively got apart from center line 1.5cm in the spinal column both sides, every some interval 2cm, the about 1 * 1cm2 of area, totally 4 points.In skin of back, inject sero-fast different dilution factors (1: 301: 40) respectively.Carrying out quantitative corresponding antigens behind the 48h attacks.The tail vein injection Radix Trichosanthis adds AZO-blue solution 1mg/kg, sacrificed by decapitation behind the 30min.
Observation index: the sero-fast local skin reaction of intradermal injection, and measure the locus coeruleus diameter that AZO-blue is oozed out.Calculate PCA and suppress percentage rate (%).PCA suppress percentage rate=(blank group locus coeruleus diameter-medication group locus coeruleus diameter)/blank group locus coeruleus diameter * 100% (Xu Shuyun, Bian Rulian, the Chen Xiu chief editor, pharmacological experimental methodology, the People's Health Publisher, in November, 1991 second edition, 1197 pages)
Table five, Chinese catalpa reality and Chinese catalpa leaf extract are to models of passive skin irritability of rats reaction influence
| Group | Number of animals (only) | Dosage g/kg | Different serum-concentration locus coeruleus diameters (cm) | |
| 1∶30 | 1∶40 | |||
| Blank | 10 | Water | 1.55±0.23 | 0.91±0.22 |
| The real extract of Chinese catalpa | 10 | 4.0 | 0.99±0.23*** | 0.61±0.22* |
| The Chinese catalpa leaf extract | 4.0 | 0.94±0.23** | 0.61±0.22* | |
| The real total glycosides extractive of Chinese catalpa | 10 | 0.15 | 0.90±0.20*** | 0.53±0.21** |
| The Chinese catalpa leaves total glycoside extract | 0.15 | 0.99±0.25** | 0.60±0.21* | |
Annotate: * and blank group be P＜0.05 relatively, and * * and blank group be P＜0.01 relatively, and * * * and blank group be P＜0.001 relatively
Result of the test sees Table five, the result as can be seen from table, the real extract of reagent Chinese catalpa, Chinese catalpa leaf extract, the real total glycosides extractive of Chinese catalpa, Chinese catalpa leaves total glycoside extract were antiserum dilution factor 1: 30,1: 40 o'clock, show significance and suppress locus coeruleus diameter (P＜0.01), suppression ratio is 36.8% and 39.6%.Show that the real extract of Chinese catalpa, Chinese catalpa leaf extract, the real total glycosides extractive of Chinese catalpa, Chinese catalpa leaves total glycoside extract all have certain inhibitory action to passive cutaneous anaphylaxis, PCA.
[embodiment three] get the real 2kg of Catalpa, water 16000ml boils and extracted 1 hour, the leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, and leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, the leaching extracting solution, merge aqueous extract, vacuum concentration gets the real extract of Catalpa to doing.
Get Catalpa root bark 2kg, water 16000ml boils and extracted 1 hour, the leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, and leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, the leaching extracting solution, merge aqueous extract, vacuum concentration gets the Catalpa leaf extract to doing.
Get the real 2kg of Catalpa, water 16000ml boils and extracted 1 hour, leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, the leaching extracting solution merges aqueous extract, through further purification, get the real total glycosides 112.4g of Catalpa, iridoid glycoside content is 51.7%.
Get Catalpa root bark 2kg, water 16000ml boils and extracted 1 hour, leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, leaching extracting solution, medicinal residues add water 12000ml again and boil extraction 1 hour, the leaching extracting solution merges aqueous extract, through further purification, get Catalpa root bark total glycosides 103.4g, iridoid glycoside content is 52.8%.
The ovalbumin aerosol sucks to draw breathes heavily test
Get 60 of 200-250g Cavia porcelluss, male and female half and half, prior to right rear leg outside intramuscular injection 4% ovalbumin normal saline solution 0.2ml/ only, while lumbar injection 4% gel aluminum hydroxide 0.2ml sensitization.From sensitization second day, animal was divided into 2 groups at random: matched group, treatment group (4.0g/kg).Treatment group Fructus catalpae ovatae crude extract (1) 4.0g/kg gastric infusion, totally 14 days, behind the last medicine, animal is put in the airtight glass bell jar, after treating peace and quiet, start air compressor, spray into 30 seconds of 3.5% ovalbumin normal saline, observe an incubation period and a number of animals of sending out the dirt tic that the tic of panting property appears in Cavia porcellus in 6 minutes with the constant voltage of 53kPa (400mmHg).(Xu Shuyun, Bian Rulian, Chen Xiu chief editor, pharmacological experimental methodology, the People's Health Publisher, in November, 1991 second edition, 1199 pages).
Table six, Catalpa reality and Catalpa root bark extract draw the influence that Cavia porcellus breathes heavily to medicine
| Group | Number of animals (n) | Dosage (g/kg) | Draw and breathe heavily incubation period (second) |
| Contrast | 10 | - | 62.7±30.6 |
| The real extract of Catalpa | 10 | 4.0 | 158.5±97.8** |
| The Catalpa root bark extract | 10 | 4.0 | 160.5±100.8** |
| The real total glycosides extractive of Catalpa | 10 | 0.15 | 149.6±98.4* |
| Catalpa root bark total glycosides extractive | 10 | 0.15 | 172.5±101.4** |
Annotate: * represents to compare P＜0.05 significant difference with the blank group, and * * represents to compare P＜0.01 difference highly significant with the blank group.
Result of the test shows, the real extract of Catalpa, Catalpa root bark extract, the real total glycosides extractive of Catalpa, Catalpa root bark total glycosides extractive all can draw the incubation period of breathing heavily Cavia porcellus by significant prolongation ovalbumin normal saline solution, compare with matched group that there were significant differences (P＜0.05), show that the real extract of Catalpa, Catalpa root bark extract, the real total glycosides extractive of Catalpa, Catalpa root bark total glycosides extractive all have certain antiasthmatic effect.
Passive cutaneous anaphylaxis test (PCA)
The rat body is divided into 5 groups at random by heavy, 10/group, ♀ ♂ half and half, sub-cage rearing, 5/cage.Be respectively 1 blank group, 4 test group.Test group adopts therapeutic to give the real extract of Catalpa, Catalpa root bark extract, the real total glycosides extractive of Catalpa, Catalpa root bark total glycosides extractive, successive administration 14d before antigen is attacked.
Antiserum Preparation: with four sole injections of above-mentioned Radix Trichosanthis aluminium hydroxide suspension, every sole injection 0.1ml, 0.4ml altogether.The 10-15d maturation, the about 10ml of eyeball blood-letting with the centrifugal 15min of 3000 commentaries on classics/min, gets upper serum and promptly gets antiserum.
Passive sensitization of skin: will test and respectively organize the rat back depilation, 2 points are respectively got apart from center line 1.5cm in the spinal column both sides, every some interval 2cm, the about 1 * 1cm2 of area, totally 4 points.In skin of back, inject sero-fast different dilution factors (1: 301: 40) respectively.Carrying out quantitative corresponding antigens behind the 48h attacks.The tail vein injection Radix Trichosanthis adds AZO-blue solution 1mg/kg, sacrificed by decapitation behind the 30min.
Observation index: the sero-fast local skin reaction of intradermal injection, and measure the locus coeruleus diameter that AZO-blue is oozed out.Calculate PCA and suppress percentage rate (%).PCA suppress percentage rate=(blank group locus coeruleus diameter-medication group locus coeruleus diameter)/blank group locus coeruleus diameter * 100% (Xu Shuyun, Bian Rulian, the Chen Xiu chief editor, pharmacological experimental methodology, the People's Health Publisher, in November, 1991 second edition, 1197 pages)
Table seven, Catalpa reality and Catalpa root bark extract are to models of passive skin irritability of rats reaction influence
| Group | Number of animals (only) | Dosage g/kg | Different serum-concentration locus coeruleus diameters (cm) | |
| 1∶30 | 1∶40 | |||
| Blank | 10 | Water | 1.57±0.24 | 0.85±0.22 |
| The real extract of Catalpa | 10 | 4.0 | 1.04±0.23*** | 0.55±0.20** |
| The Catalpa root bark extract | 10 | 4.0 | 0.98±0.22*** | 0.55±0.20** |
| The real total glycosides of Catalpa | 10 | 0.15 | 0.96±0.21*** | 0.61±0.20* |
| Catalpa root bark total glycosides | 10 | 0.15 | 0.90±0.19*** | 0.64±0.21* |
Annotate: * and blank group be P＜0.05 relatively, and * * and blank group be P＜0.01 relatively, and * * * and blank group be P＜0.001 relatively
Result of the test sees Table seven.The result as can be seen from table, the real extract of reagent Catalpa, Catalpa root bark extract, the real total glycosides extractive of Catalpa, Catalpa root bark total glycosides extractive were antiserum dilution factor 1: 30,1: 40 o'clock, show significance and suppress locus coeruleus diameter (P＜0.01), suppression ratio is 36.8% and 39.6%.Show that the real extract of Catalpa, Catalpa root bark extract, the real total glycosides extractive of Catalpa, Catalpa root bark total glycosides extractive all have certain inhibitory action to passive cutaneous anaphylaxis, PCA.
Claims (7)
1, catalpa is in the medicine of preparation treatment anaphylactic disease or the application of pharmaceutical composition.
2, according to the application described in the claim 1, its feature catalpa extract is in the medicine of preparation treatment anaphylactic disease or the application of pharmaceutical composition.
3, according to the application described in the claim 2, its feature catalpa iridoid total glucoside extract is in the medicine of preparation treatment anaphylactic disease or the application of pharmaceutical composition.
4, according to the application described in the claim 3, wherein, the iridoid glycoside content of catalpa iridoid total glucoside extract is greater than 50%.
5, according to the application described in claim 1 or 2 or 3, wherein, anaphylactic disease is an allergic asthma.
6, according to the application described in claim 1 or 2 or 3 or 4, wherein, catalpa is Catalpa ovata Don. or Chinese catalpa or Catalpa bungei or Catalpa.
7, according to the application described in claim 1 or 2 or 3 or 4 or 5 or 6, it is characterized in that making oral formulations, or make injection or make inhalant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410103549XA CN1332675C (en) | 2004-12-30 | 2004-12-30 | Medicine application of catalpa and extractive for anti allergic disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410103549XA CN1332675C (en) | 2004-12-30 | 2004-12-30 | Medicine application of catalpa and extractive for anti allergic disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1795882A CN1795882A (en) | 2006-07-05 |
| CN1332675C true CN1332675C (en) | 2007-08-22 |
Family
ID=36817337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200410103549XA Expired - Fee Related CN1332675C (en) | 2004-12-30 | 2004-12-30 | Medicine application of catalpa and extractive for anti allergic disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1332675C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102119421B1 (en) * | 2017-04-25 | 2020-06-05 | 재단법인 경기도경제과학진흥원 | Composition for Anti-Allergy Using an Extract of Catalpa ovata |
| JP7170028B2 (en) * | 2020-12-23 | 2022-11-11 | 禎吉郎 東 | Antiallergic composition and method for producing antiallergic composition |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1189373A (en) * | 1998-01-22 | 1998-08-05 | 廖凤霞 | Medicinal wine for treating cancer |
-
2004
- 2004-12-30 CN CNB200410103549XA patent/CN1332675C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1189373A (en) * | 1998-01-22 | 1998-08-05 | 廖凤霞 | Medicinal wine for treating cancer |
Non-Patent Citations (1)
| Title |
|---|
| 梓树植物化学成分研究进展 王奇志等，中草药，第34卷第7期 2003 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1795882A (en) | 2006-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103768308B (en) | A kind of pharmaceutical composition that is used for the treatment of the infection of the upper respiratory tract and preparation method thereof | |
| CN101347477B (en) | Medicament composition for treating rheumatoid arthritis | |
| CN101549016B (en) | Traditional Chinese medicine composition for treating acute and chronic pharyngitis and preparation method thereof | |
| CN100459999C (en) | Medicine for treating rheumatism | |
| CN1332675C (en) | Medicine application of catalpa and extractive for anti allergic disease | |
| CN115025112B (en) | Application of radix angelicae polysaccharide in preparation of medicine for preventing and treating ulcerative colitis | |
| CN103751349B (en) | Traditional Chinese medicine composition for treating rhinitis and preparation method of composition | |
| CN114404462B (en) | Composition and application thereof in preparation of medicine for treating gastric injury and/or gastric ulcer | |
| CN105267501A (en) | Traditional Chinese medicine composition for treating poisonous snake bites | |
| CN1284353A (en) | Dengtai tree extract and its preparation and use | |
| CN100349590C (en) | Medicinal use of glutinous rehmannia stem and leaf and its extract for preventing asthma and anti-allergy | |
| CN100349589C (en) | Medical application of rehmannia root extractive in resisting asthma and allergy | |
| CN107638497B (en) | Traditional Chinese medicine composition for treating venomous snake bite and preparation method and application thereof | |
| CN102670865A (en) | Process for extracting active ingredients of American eleutherine rhizome | |
| WO2015135372A1 (en) | Application of isoforskolin in preventing and treating chronic obstructive pulmonary disease | |
| CN106539979A (en) | A kind of Chinese medicine preparation for treating allergic rhinitises | |
| CN1698841A (en) | Medical usage of picrorhiza rhizome total glycoside extract | |
| CN101015622A (en) | Medicinal use of radix rehmanniae total glucosides extractive and preparing method thereof | |
| CN108992580A (en) | Chinese medicine composition and preparation method thereof for preventing phlegm from forming and stopping coughing | |
| CN101549051A (en) | Traditional Chinese medicine composition for treating asthma and preparation method thereof | |
| CN113827636B (en) | Lung-clearing mixture containing Tibetan four ingredients and application thereof in preparation of medicines for treating respiratory system diseases | |
| CN103110737B (en) | Traditional Chinese medicine composition for treating gynecologic inflammation and preparation method thereof | |
| CN100341532C (en) | External use preparation for treating bliser tetter | |
| KR20050121094A (en) | Preventive and curative extracts from siegesbeckiae herba for respiratory organ disease | |
| CN1465389A (en) | Daqinglong decoction and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Beijing Marshall Biotechnology Co., Ltd. Assignor: Luo Hesheng Contract fulfillment period: 2009.10.27 to 2015.10.27 contract change Contract record no.: 2009110000262 Denomination of invention: Medicine application of catalpa and extractive for anti allergic disease Granted publication date: 20070822 License type: Exclusive license Record date: 2009.11.2 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.10.27 TO 2015.10.27; CHANGE OF CONTRACT Name of requester: BEIJING MARSHALL BIOTECHNOLOGY CO., LTD. Effective date: 20091102 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070822 Termination date: 20151230 |
|
| EXPY | Termination of patent right or utility model |